Akoya Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	20.36	11.78	83.13	74.23	113.08	17.01
Short-Term Investments	7.19	23.26	-	6.99	-	-
Cash & Short-Term Investments	27.54	35.04	83.13	81.22	113.08	17.01
Cash Growth	-55.27%	-57.85%	2.35%	-28.18%	564.94%	-21.48%
Accounts Receivable	11.74	13.78	16.99	9.73	9.44	6.47
Other Receivables	-	-	-	-	5.09	-
Receivables	11.74	13.78	16.99	9.73	14.54	6.47
Inventory	22.85	24.32	17.88	14.49	9.01	4.26
Prepaid Expenses	4.07	3.26	3.79	6.76	4.18	0.96
Other Current Assets	-	0.33	-	-	-	-
Total Current Assets	66.21	76.73	121.79	112.2	140.81	28.7
Property, Plant & Equipment	12.09	12.98	20.66	22.45	7.49	5.53
Goodwill	18.26	18.26	18.26	18.26	18.26	18.26
Other Intangible Assets	13.85	14.56	17.41	20.05	21.15	22.71
Long-Term Deferred Tax Assets	-	0.13	0.04	0.04	-	-
Long-Term Deferred Charges	-	-	0.33	0.33	-	0.27
Other Long-Term Assets	2.24	2.34	1.88	2.71	3.19	2.19
Total Assets	112.65	125.01	180.37	176.03	190.91	77.66
Accounts Payable	10.29	8.76	11.78	10.63	9.44	5.07
Accrued Expenses	8.58	8.5	10.43	11.16	12.28	5.43
Current Portion of Long-Term Debt	76.49	-	-	-	-	1.03
Current Portion of Leases	3.21	3.28	3.45	3.63	0.27	0.2
Current Unearned Revenue	6.52	6.55	6.69	6.28	4.48	3.84
Other Current Liabilities	2.99	2.35	3.01	5.36	1.21	1.59
Total Current Liabilities	108.08	29.44	35.35	37.06	27.68	17.16
Long-Term Debt	-	76.18	75.25	63.28	32.47	33.49
Long-Term Leases	4.02	4.68	7	8.88	0.2	0.28
Long-Term Unearned Revenue	2.78	3.06	3.19	2.11	1.33	1.01
Long-Term Deferred Tax Liabilities	0.14	0.13	0.04	0.09	0.03	0.17
Other Long-Term Liabilities	3.51	3.91	5.77	6.04	7.85	7.47
Total Liabilities	118.54	117.41	126.6	117.45	69.56	59.58
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	295.2	293.02	283.84	225.33	217.46	-
Retained Earnings	-301.09	-285.44	-230.07	-166.75	-96.11	-52.28
Comprehensive Income & Other	-0	0.01	-	-0.01	-	-
Total Common Equity	-5.89	7.6	53.77	58.58	121.35	-52.28
Shareholders' Equity	-5.89	7.6	53.77	58.58	121.35	18.08
Total Liabilities & Equity	112.65	125.01	180.37	176.03	190.91	77.66
Total Debt	83.72	84.15	85.71	75.78	32.94	34.99
Net Cash (Debt)	-56.18	-49.11	-2.58	5.43	80.14	-17.99
Net Cash Growth	-	-	-	-93.22%	-	-
Net Cash Per Share	-1.13	-0.99	-0.06	0.14	2.98	-7.59
Filing Date Shares Outstanding	49.88	49.82	49.14	38.34	37.48	2.56
Total Common Shares Outstanding	49.84	49.57	49.12	38.29	37.42	2.56
Working Capital	-41.87	47.29	86.45	75.14	113.13	11.53
Book Value Per Share	-0.12	0.15	1.09	1.53	3.24	-20.39
Tangible Book Value	-38	-25.23	18.1	20.27	81.94	-93.26
Tangible Book Value Per Share	-0.76	-0.51	0.37	0.53	2.19	-36.37
Machinery	13.68	13.31	14.52	12.52	9.98	6.53
Leasehold Improvements	5.28	5.25	5.88	3.98	1.57	1.26

Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q